CareDx (NASDAQ:CDNA) Issues Quarterly Earnings Results

CareDx (NASDAQ:CDNA) posted its quarterly earnings results on Thursday. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.15, FiscalAI reports. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The business’s revenue for the quarter was up 52.2% on a year-over-year basis. During the same period last year, the business earned ($0.16) EPS.

Here are the key takeaways from CareDx’s conference call:

• Q2 revenue rose 52% to $132 million, while testing services revenue increased 61% to $100 million and adjusted EBITDA reached $25 million, or 19% of revenue. The company also ended the quarter with $374 million in cash and no debt.
• CareDx raised its 2026 guidance to $490 million–$500 million in revenue and $66 million–$78 million in adjusted EBITDA, including $24 million of second-half specialty oncology revenue and 258,000–266,000 tests for the year.
• Transplant testing growth remains strong, with Q2 volume up 17% to 58,000 tests as both surveillance and for-cause use expanded. Management cited broader clinical adoption, improved workflows, and evidence supporting AlloSure’s use in risk assessment and treatment monitoring.
• The company reported progress across its growth pipeline and NavDx acquisition, including a planned 2027 AlloHeme commercial launch, a 2026 clinical-study launch for HistoMap Kidney, and integration initiatives intended to expand NavDx adoption and improve reimbursement and workflow efficiency.
• Management characterized its outlook as prudent while it integrates NavDx billing and operating systems; specialty oncology is currently modeled at roughly 63% gross margin and may require additional investment, although CareDx continues to target approximately 20% long-term adjusted EBITDA margins.

CareDx Price Performance

CDNA traded up $2.69 on Thursday, reaching $38.10. 1,741,217 shares of the company traded hands, compared to its average volume of 802,924. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -238.12 and a beta of 2.43. The stock’s 50 day moving average price is $27.82 and its 200-day moving average price is $22.31. CareDx has a 52-week low of $11.26 and a 52-week high of $40.47.

Insider Buying and Selling

In other news, Director Hannah Valantine sold 12,103 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director directly owned 36,686 shares in the company, valued at $847,813.46. The trade was a 24.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the completion of the transaction, the chief executive officer directly owned 661,959 shares in the company, valued at $19,355,681.16. This trade represents a 5.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 78,936 shares of company stock valued at $2,093,708. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CDNA. State Street Corp increased its position in CareDx by 6.7% in the 4th quarter. State Street Corp now owns 2,737,752 shares of the company’s stock worth $51,579,000 after purchasing an additional 171,303 shares during the last quarter. Bamco Inc. NY raised its stake in shares of CareDx by 11.2% during the 2nd quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock worth $47,593,000 after purchasing an additional 245,651 shares in the last quarter. Deerfield Management Company L.P. acquired a new stake in shares of CareDx during the 3rd quarter valued at about $31,857,000. Dimensional Fund Advisors LP lifted its holdings in shares of CareDx by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,309,980 shares of the company’s stock valued at $24,681,000 after buying an additional 93,456 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock valued at $19,703,000 after buying an additional 170,504 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CDNA. William Blair raised CareDx to a “hold” rating in a research note on Thursday, July 16th. BTIG Research upped their target price on CareDx from $28.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. Craig Hallum restated a “hold” rating and set a $35.00 price objective on shares of CareDx in a report on Thursday, July 16th. Finally, Weiss Ratings lowered shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CareDx has an average rating of “Hold” and a consensus price target of $33.67.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.